Caliper Life Sciences to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19

HOPKINTON, Mass., July 18, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for life science companies, today announced that Kevin Hrusovsky, President and CEO, has been invited to ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19th and will be joined by family, management and several strategic customers to participate in this special event. This event highlights Caliper's successful transformation into a leading diversified life sciences tools company.  

Caliper's strategy is to commercialize disruptive technologies that revolutionize and personalize health care through improved patient diagnosis, prognosis and treatment by developing market-leading tools and services for pre-clinical and clinical imaging, digital pathology, sample preparation for next generation sequencing, molecular and companion diagnostics, stem cell research, as well as the development of biotherapeutics and vaccines.  Over the past seven years, Caliper has grown core products and services, increased margins and become operating cash flow positive by completing several strategic acquisitions and  divesting non-core product lines.  Caliper reported organic revenue growth of over 20% in the first quarter of 2011.  The market has rewarded Caliper's success with an increase in its stock price during each of 2009 and 2010 of over 150%, and an approximate 30% increase year-to-date in 2011.  

"Ringing the Opening Bell is a great opportunity to recognize our families, employees, customers, collaborators and investors for their dedicated support in building Caliper into a successful high growth company with strong potential for making life changing impact in health care.  Their hard work and inspiring 'can do' attitudes have enabled Caliper to become a diversified, high growth tools provider with attractive short- and long-term prospects," said Kevin Hrusovsky, President and CEO of Caliper.  "We are excited about our future as we launch important products into attractive markets designed to revolutionize and personalize medicine and transform 'sick care' to health care.  We believe Caliper's product and technology platforms have the potential to increase our annual organic revenue growth to 15% or greater, with incremental revenues contributing at least 60% of revenue to operating margin."  

A live webcast of The NASDAQ Stock Market Opening Bell can be viewed at: http://www.nasdaq.com/about/marketsitetowervideo.asx or http://social.nasdaqomx.com, as well as live on major broadcast news outlets including CNBC, FOX Business Network, Reuters TV, and Bloomberg TV.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently.  Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

The statements in this press release regarding future events, including Caliper's belief that its product and technology platforms will enable Caliper to increase its annual organic revenue growth to 15% or greater, with incremental revenues contributing at least 60% of revenue to operating margin, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended.  These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that Caliper's expectations regarding demand for its products and services may not materialize if capital spending by Caliper's customers declines, if customers do not purchase newly developed or acquired product lines as rapidly as Caliper believes that they will, or if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its microfluidic and imaging systems and products and its assay development and services product offerings.  Further information on risks faced by Caliper are detailed under the caption "Risks Related to Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2010. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

Caliper is a registered trademark of Caliper Life Sciences, Inc.

SOURCE Caliper Life Sciences, Inc.